China's Innovent Biologics H1 revenue, profit rise on strong product sales

Innovent Biologics

25/08/2026 13:48

Overview
China biopharma firm's H1 revenue rose 44.8% yr/yr on strong product sales growth
Net profit for H1 grew 50.2% yr/yr, supported by operational efficiency gains
Company cites expanded product portfolio and new partnerships as growth drivers

Outlook
Company expects continued revenue and profit growth as new products and indications are approved
Innovent anticipates multiple late-stage clinical trial readouts and regulatory submissions by end-2026

Result Drivers
DUAL-ENGINE STRATEGY - Co said revenue growth was driven by execution of its dual-engine strategy, with accelerated contributions from general biomedicine and ramp-up of newly NRDL-listed oncology products
OPERATIONAL EFFICIENCY - Co attributed profit growth to strong revenue ramp-up and continued improvement in operational efficiency
TAKEDA LICENSE REVENUE – Innovent recognized part of Takeda's upfront payment as RMB309.9 mln of license-fee income after meeting performance obligations

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 8.62 bln
 
H1 Net Income
 
RMB 1.25 bln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 30 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Innovent Biologics, Inc. is HK$114.56, about 14.4% above its August 25 closing price of HK$100.10
The stock recently traded at 51 times the next 12-month earnings vs. a P/E of 57 three months ago

Reuters Recommended Reads
Aug 24 - China's InnoCare Pharma H1 revenue surges, partly on orelabrutinib growth
Aug 24 - China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost
Aug 24 - China's RemeGen H1 revenue soars on drug sales, AbbVie deal

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Press Release s3://eap-prd-eu-west-1-source-content/eap_feed_proxy/fingerpost/HKSW/2026-08-25/55fe34ab-fc27-48d9-af09-12a91a804d75.file
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)